Clinical Trial Update: The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating the efficacy and safety of the bispecific anti-PD-1/PD-L1 antibody IBI318 in combination with lenvatinib for non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IBI318
• LENVIMA (lenvatinib)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING